ClinicalTrialsFinder
RecruitingEarly Phase 1NCT06181513

Probiotics in Mild Alzheimer's Disease

Effect of Probiotics on Cognitive Functioning of Patients With Mild Alzheimer's Disease

Sponsor

University of Nicosia

Enrollment

40 participants

Start Date

Dec 19, 2022

Study Type

INTERVENTIONAL

Conditions

Neurodegenerative DiseasesCognition Disorders in Old Age

Summary

The main objective is to investigate whether administration of probiotics to patients with mild Alzheimer's Disease (AD) reduces neuroinflammation, improves cognitive function and modifies neurophysiological measures, compared to a patient group that receives placebo (no active probiotics).

Eligibility

Min Age: 65 YearsMax Age: 85 Years

Inclusion Criteria3

  • Adults ≥65 years, able to give consent
  • Mini-Mental State Examination (MMSE) scores 19-23 (mild AD)
  • approximately equal male:female ratio

Exclusion Criteria15

  • Inability to give consent
  • other neurological disease
  • relevant psychiatric disorders (e.g. major depression)
  • gastrointestinal/metabolic conditions
  • history of alcohol/substance dependence
  • use of systemic antibiotics in the previous 6 months
  • corticosteroid use
  • immune stimulating medications
  • immunosuppressive agents
  • probiotics consumption in the previous 6 months.
  • immunosuppression
  • structural heart disease
  • neutropenia
  • radiation
  • active intestinal disease

Interventions

DRUGProbiotic Blend Capsule

20 million CFU (Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus rhamnosus, Lactobacillus helveticus, Bifidobacterium breve)

Locations(1)

The Cyprus Institute of Neurology and Genetics

Nicosia, Cyprus

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06181513

Related Trials

Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease

NCT0483830110 locations

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

NCT05508789141 locations

Real-world Clinical Response to Trazodone in Italy, Poland, and Romania

NCT073776821 location

Slowing Cognitive Decline in Alpha-synucleinopathies by Enhancing Physical Activity

NCT073243301 location

Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia

NCT057418533 locations